top of page

NCI-2022-10661

Updated: Feb 21

A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination with Tremelimumab ± Lenvatinib Given Concurrently with Transarterial Chemoembolization (TACE) Compared to TACE Alone in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-3)



For more information about the trial, click the link below:

Clinical Trial Site: Sinai


To see all available clinical trials click here.



 
 
 

Recent Posts

See All
NCI-2025-06021

Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer (TRIPL) This is a research study exploring how combining radiation therapy with dual immune check

 
 
 
NCI-2024-05588

A Randomized Phase III Trial INcorporating Pathologic Complete ReSponse in Participants with Early StaGe Non Small Cell Lung Cancer to Optimize ImmunotHerapy in the AdjuvanT Setting (INSIGHT) The INSI

 
 
 
NCI-2022-08569

Randomized Phase III Trial of mFOLFIRINOX /- Nivolumab vs. FOLFOX /- Nivolumab for First-Line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma This randomized Phase III research

 
 
 

Comments

bottom of page